Matthew T. Chang

19.2k total citations · 2 hit papers
18 papers, 2.3k citations indexed

About

Matthew T. Chang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Matthew T. Chang has authored 18 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Matthew T. Chang's work include Cancer Genomics and Diagnostics (8 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Melanoma and MAPK Pathways (2 papers). Matthew T. Chang is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Melanoma and MAPK Pathways (2 papers). Matthew T. Chang collaborates with scholars based in United States, France and Australia. Matthew T. Chang's co-authors include Barry S. Taylor, David B. Solit, Nikolaus Schultz, Alison M. Schram, Philip Jonsson, Alexander Drilon, Sizhi Paul Gao, Jianjiong Gao, Jocelyn Chapman and Nicholas D. Socci and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Matthew T. Chang

17 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

2015 492 citations Matthew T. Chang, Saurabh Asthana et al. Nature Biotechnology profile →
Genome doubling shapes the evolution and prognosis of advanced cancers

2018 343 citations Craig M. Bielski, Ahmet Zehir et al. Nature Genetics profile →

Peers

Countries citing papers authored by Matthew T. Chang

Since Specialization

Citations

This map shows the geographic impact of Matthew T. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew T. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew T. Chang more than expected).

Fields of papers citing papers by Matthew T. Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew T. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew T. Chang. The network helps show where Matthew T. Chang may publish in the future.

Co-authorship network of co-authors of Matthew T. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew T. Chang. A scholar is included among the top collaborators of Matthew T. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew T. Chang. Matthew T. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Nucleation and dissolution mechanism underlying amyotrophic lateral sclerosis/frontotemporal lobar dementia-linked fused in sarcoma condensates 2023 ·iScience ·(unknown), Matthew T. Chang, (unknown), (unknown), Laura R. Ganser, Sua Myong	5
2	AKT mutant allele-specific activation dictates pharmacologic sensitivities 2022 ·Nature Communications ·Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, (unknown), Mark T.A. Donoghue, (unknown), Swati Patel, Sizhi Paul Gao, (unknown), Sarah Phillips, Tara E. Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor	26
3	Identifying transcriptional programs underlying cancer drug response with TraCe-seq 2021 ·Nature Biotechnology ·Matthew T. Chang, Fergus Shanahan, (unknown), Steven T. Staben, Lewis Gazzard, Sayumi Yamazoe, Ingrid E. Wertz, Robert Piskol, Yeqing Angela Yang, Zora Modrušan, Benjamin Haley, Marie Evangelista, Shiva Malek, Scott A. Foster, Xin Ye	24
4	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways 2020 ·Cancer Discovery ·(unknown), Thijs J. Hagenbeek, Ho-June Lee, Jason Li, Christopher M. Rose, Eva Lin, Mamie Yu, Scott E. Martin, Robert Piskol, Jennifer A. Lacap, Deepak Sampath, Victoria C. Pham, Zora Modrušan, Jennie R. Lill, Christiaan Klijn, Shiva Malek, Matthew T. Chang, Anwesha Dey	37
5	An integrated molecular profile of endometrioid ovarian cancer 2020 ·Gynecologic Oncology ·William E. Pierson, (unknown), Matthew T. Chang, Lee-may Chen, David A. Quigley, Alan Ashworth, Jocelyn Chapman	46
6	The Hippo Pathway as a Driver of Select Human Cancers 2020 ·Trends in cancer ·Aishwarya Kulkarni, Matthew T. Chang, Joseph H.A. Vissers, Anwesha Dey, Kieran F. Harvey	50
7	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties 2018 ·Cancer Discovery ·Yijun Gao, Matthew T. Chang, Daniel J. McKay, Na Na, Bing Zhou, Rona Yaeger, Neilawattie M. Torres, (unknown), Matthias Drosten, Mariano Barbacid, Giordano Caponigro, Darrin D. Stuart, Henrik Moebitz, David B. Solit, Omar Abdel‐Wahab, Barry S. Taylor, Zhan Yao, Neal Rosen	87
8	Genome doubling shapes the evolution and prognosis of advanced cancers breakdown → 2018 ·Nature Genetics ·Craig M. Bielski, Ahmet Zehir, Alexander Penson, Mark T.A. Donoghue, Walid K. Chatila, Joshua Armenia, Matthew T. Chang, Alison M. Schram, Philip Jonsson, Chaitanya Bandlamudi, Pedram Razavi, Gopa Iyer, Mark E. Robson, Zsofia K. Stadler, Nikolaus Schultz, José Baselga, David B. Solit, David M. Hyman, Michael F. Berger, Barry S. Taylor	343
9	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer 2018 ·Cancer Cell ·Craig M. Bielski, Mark T.A. Donoghue, Mayur Gadiya, Aphrothiti J. Hanrahan, Helen Won, Matthew T. Chang, Philip Jonsson, Alexander Penson, Alexander N. Gorelick, Christopher Harris, Alison M. Schram, Aijazuddin Syed, Ahmet Zehir, Paul B. Chapman, David M. Hyman, David B. Solit, Kevin Shannon, Sarat Chandarlapaty, Michael F. Berger, Barry S. Taylor	59
10	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS 2017 ·Nature ·Zhan Yao, Rona Yaeger, Vanessa Rodrik-Outmezguine, Anthony Tao, Neilawattie M. Torres, Matthew T. Chang, Matthias Drosten, HuiYong Zhao, Franco Cecchi, Todd Hembrough, Judith Michels, Hervé Baumert, Linde A. Miles, Naomi Campbell, Elisa de Stanchina, David B. Solit, Mariano Barbacid, Barry S. Taylor, Neal Rosen	349
11	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets 2017 ·Genome Medicine ·Jianjiong Gao, Matthew T. Chang, Hannah C. Johnsen, Sizhi Paul Gao, Brooke E. Sylvester, S. Onur Sumer, Hongxin Zhang, David B. Solit, Barry S. Taylor, Nikolaus Schultz, Chris Sander	140
12	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance 2017 ·Nature Reviews Clinical Oncology ·Alison M. Schram, Matthew T. Chang, Philip Jonsson, Alexander Drilon	226
13	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma 2016 ·Nature Genetics ·Amanda R. Moore, Emilie Ceraudo, Jessica Sher, Youxin Guan, Alexander N. Shoushtari, Matthew T. Chang, Jenny Q. Zhang, Edward Walczak, Manija A. Kazmi, Barry S. Taylor, Thomas Huber, Ping Chi, Thomas P. Sakmar, Yu Chen	214
14	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity breakdown → 2015 ·Nature Biotechnology ·Matthew T. Chang, Saurabh Asthana, Sizhi Paul Gao, Byron Lee, Jocelyn Chapman, Cyriac Kandoth, Jianjiong Gao, Nicholas D. Socci, David B. Solit, Adam B. Olshen, Nikolaus Schultz, Barry S. Taylor	492
15	Clinical Sequencing Contributes to aBRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course 2015 ·Journal of the National Comprehensive Cancer Network ·Jocelyn Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles Zaloudek, Stefanie Ueda, Eric A. Collisson, Barry S. Taylor	2
16	Clinical Application of Pharmacogenetics: Focusing on Practical Issues 2015 ·Pharmacogenomics ·Matthew T. Chang, Jeanette McCarthy, Jaekyu Shin	7
17	Copy number alteration burden predicts prostate cancer relapse 2014 ·Proceedings of the National Academy of Sciences ·Haley Hieronymus, Nikolaus Schultz, Anuradha Gopalan, Brett S. Carver, Matthew T. Chang, Yonghong Xiao, Adriana Heguy, Kety Huberman, Melanie Bernstein, Melissa Assel, Rajmohan Murali, Andrew J. Vickers, Peter T. Scardino, Chris Sander, Victor E. Reuter, Barry S. Taylor, Charles L. Sawyers	231
18	Machine Vision System for Measuring Subsurface Damage 1992 ·John E. Greivenkamp, Matthew T. Chang	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact